Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Medicaid patients in California and New Jersey, USA, receiving treatment for opioid use disorder stayed in treatment longer on sublingual buprenorphine than on extended-release naltrexone, but the risk of overdose was similar. Most patients in this study discontinued medication within 6 months, regardless of which medication was initiated.
Authors
- Matisyahu Shulman (ORCID: https://orcid.org/0000-0002-2941-8895)
- Rachael K. Ross (ORCID: https://orcid.org/0000-0002-2049-6918)
- Kara E. Rudolph (ORCID: https://orcid.org/0000-0002-9417-7960)
- Elizabeth A. Stuart (ORCID: https://orcid.org/0000-0002-9042-8611)
- Edward V. Nunes (ORCID: https://orcid.org/0000-0002-2055-3425)
- Noa Krawczyk (ORCID: https://orcid.org/0000-0002-7396-3938)
- Mark Olfson
Institutions
- Johns Hopkins University (US)
- Columbia University Irving Medical Center (US)
- New York Psychoanalytic Society and Institute (US)
- New York State Psychiatric Institute
- New York University (US)
- Columbia University (US)
Publication Details
- Journal
- Addiction
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1111/add.16630
- Citations
- 9
- Primary Topic
- Opioid Use Disorder Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.89
Funders
- National Institutes of Health
- National Institute on Drug Abuse